There is an urgent need to transform care and improve outcomes in immune-mediated diseases where patients continue to face unacceptable outcomes such as permanent organ damage, uncontrolled disease activity and even death.
Ben venga l’opportunità di migliorare l’accesso ai farmaci, con tutte le sue ricadute: cliniche in primis, ma pure economiche e sociali. A patto, però, che la Commissione Europea faccia il possibile (per quel che è nelle sue potenzialità) per rilanciare anche la ricerca clinica in ambito cardiovascolare.
Dopo le cellule Carcik per la leucemia mieloide acuta, i ricercatori della Fondazione Tettamanti di Monza hanno messo a punto anche una versione della terapia per la leucemia linfoblastica acuta di tipo b.
With access to more data than ever before – including data from patient records, laboratory research and experiments, clinical studies and decentralised trials, and scientific publications – now is the time for the industry to modernise, become data-led and boost patient experience.
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 25% in overall population and by 37% in patients with non-squamous tumours.
Datopotamab deruxtecan is the first antibody drug conjugate to demonstrate statistically significant improvement in PFS over docetaxel in this setting of high unmet need.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy setting.
AstraZeneca and Daiichi Sankyo’s Enhertu showed a median progression-free survival of 6.9 months and median overall survival of 13.4 months in the overall trial population.
Results reaffirm potential role of Enhertu as a tumour-agnostic therapy for previously treated patients with HER2-expressing solid tumours and support ongoing discussions with global regulatory authorities.
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus Imfinzi showed a confirmed objective response rate of 79%. Two ongoing Phase III trials are evaluating datopotamab deruxtecan in patients with triple-negative breast cancer.
